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Abstract
Endocrine therapy (ET) is the cornerstone of adjuvant therapy for hormone-receptor positive (HR
+) breast cancer. The survival gap between African-American (AA) and white women with breast 
cancer is most pronounced in HR+ subtypes, and could be related to differences in ET use. The 
relationship between race and initiation of ET is not well defined. We investigated patterns of ET 
initiation by race in a diverse cohort of women covered by commercial health insurance. We 
identified 2,640 women with incident HR+ breast cancer in the North Carolina Central Cancer 
Registry whose records linked to commercial insurance claims using the Integrated Cancer 
Information and Surveillance System (ICISS) database. The sample included women age<65 years 
diagnosed with stage I–III HR+ cancers between 2004 and 2009. We used multivariate Poisson 
regression to examine the effect of race on likelihood of initiating ET. 14 % of women did not 
initiate ET within 12 months of diagnosis. AA women were 17 % less likely to initiate ET than 
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whites (aRR 0.83, 95 % CI 0.74–0.93). When analyzed by subset, racial disparities persisted 
among women who received chemotherapy (aHR 0.67, 95 % CI 0.56–0.80) but not among women 
who did not receive chemotherapy (aHR 0.96, 95 % CI 0.76–1.21). AA women in our sample 
were less likely to initiate ET than whites, and this disparity was concentrated among 
chemotherapy-treated women. ET under-utilization may contribute to the racial survival gap in HR
+ breast cancer, and represents an opportunity for intervention to reduce breast cancer disparities.
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Background
African-American women with hormone-receptor positive breast cancer have higher rates of 
recurrence and poorer survival compared to their white counterparts, and this pattern has 
been disturbingly stable over the past 30 years even as overall breast cancer outcomes have 
improved [1, 2]. Despite an overall favorable prognosis for estrogen-sensitive breast tumors, 
African-American women with hormone-receptor positive breast cancer experience a greater 
disparity in recurrence and survival outcomes than in any other breast cancer phenotype 
including aggressive variants such as triple negative breast cancer [3]. Although this 
disparity is partially explained by advanced stage at presentation and under-treatment [4], 
the racial survival gap persists after controlling for presenting stage and receipt of adjuvant 
therapies including chemotherapy and radiation. [5].
Endocrine therapy (ET) is an essential element of treatment for hormone-receptor positive 
breast cancer. Taken as an oral medication daily for 5 to 10 years, oral anti-estrogen 
medications including tamoxifen and aromatase inhibitors decrease the risk of breast cancer 
recurrence by an estimated 40 % and the risk of death by one-third [6]. Despite their 
impressive efficacy, not all breast cancer survivors initiate endocrine therapy medications. 
Previous studies suggest that 10–30 % of women eligible for endocrine therapy, depending 
on the population studied, never initiate treatment [7, 8]. Of those who initiate, many 
discontinue treatment early or skip a significant number of doses [9, 10]. Altogether, 
approximately half of women are not taking their endocrine therapy effectively by the end of 
5 years of treatment [11]. This under-utilization of endocrine therapy has been tied to worse 
breast cancer recurrence and survival outcomes [12].
Under-utilization of endocrine therapy by African-American women may contribute to the 
survival gap in hormone-receptor positive breast cancer, but potential disparities in 
endocrine therapy utilization have not been well studied. Under-treatment of minority 
women compared to their white peers has been a tragic and consistent pattern across other 
breast cancer therapies, including definitive surgery, chemotherapy, and radiation [13, 14]. 
However, racial disparities in use of endocrine therapy have not been as well explored for 
several reasons. Data regarding oral medication use in cancer registries and other large 
observational databases have historically been limited or unavailable. Previous studies 
broadly examining racial disparities in adjuvant treatment have had incomplete information 
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regarding ET use, while studies specifically examining patterns of ET utilization using 
claims data have been limited by small African-American samples or have examined only 
uniformly underserved populations such as Medicaid patients [8, 15, 16]. One study by 
Short and colleagues examining medical records of commercially insured health plans in the 
Southern United States found a significantly lower rate of ET prescription for hormone-
receptor positive disease among African-Americans compared to whites, but was not able to 
examine whether the prescriptions were filled or continued [17]. A second study using data 
from the Women’s Health Initiative did not find racial differences in self-reported use of 
adjuvant endocrine therapy, but was limited by lack of objective data to con-firm self-
reported medication taking behavior [18].
In the current study, our objective was to analyze racial differences in endocrine therapy 
initiation patterns among a racially diverse cohort of women with newly diagnosed breast 
cancer in the Integrated Cancer Information and Surveillance System (ICISS) database. 
ICISS links clinical information from the North Carolina Central Cancer Registry to claims 
data from a variety of insurance payers across the state. We leveraged the racial diversity of 
North Carolina and the strengths of registry-claims linked data, including pharmacy claims 
for oral medications, to examine the association between race and ET initiation.
Methods
Data
We utilized three linked data sources from the Integrated Cancer Information and 
Surveillance System (ICISS). ICISS is a data resource developed by the University of North 
Carolina Lineberger Comprehensive Cancer Center. It includes cancer case data from the 
North Carolina Central Cancer Registry and administrative and claims data for North 
Carolinians from Medicare, Medicaid, and beneficiaries in privately insured health plans. 
The registry-claims linked data in their entirety cover approximately 85 % of the North 
Carolina population with cancer through 2009. For the current study, we identified patients 
in the NC cancer registry whose files linked to insurance claims from privately insured 
health plans with reliable pharmacy claims data. Data from public insurers including 
Medicare and Medicaid were not used for this analysis due to lack of reliable pharmacy 
claims data during the study period. Cancer registry data were available for all incident 
cancer cases diagnosed from 2004 to 2009. The insurance administrative data include 
monthly enrollment data, inpatient and outpatient medical claims, and outpatient 
prescription drug claims.
Study Sample
We included women ages 64 and under who were identified in the North Carolina Central 
Cancer Registry as having a first and only diagnosis of stage I–III breast cancer between 
2004 and 2009 and who had linked insurance claims from a commercial or SHP plan (N = 
9,586). We excluded women who did not have continuous enrollment in the health plan in 
the month prior to and the 12 months following their breast cancer diagnosis date (N = 
5,131) because the outcome of interest (initiation of endocrine therapy within 1 year) could 
not be ascertained in this group. Due to lack of specificity in registry data regarding the 
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identification of second breast cancers as recurrences, second primaries or distant 
metastases, we excluded women who had a second breast cancer diagnosis in the cancer 
registry after their index diagnosis (N = 91). To ensure that included women had claims 
adequately reflective of their health care utilization, we excluded women who had no 
evidence of medical or pharmacy benefits use in the year following diagnosis (N = 295). We 
also excluded patients who did not receive definitive breast cancer surgery (i.e., mastectomy 
or breast-conserving surgery) within 9 months of diagnosis (N = 57). We excluded women 
who had initiated endocrine therapy prior to their primary surgery (N = 18) due to 
uncertainty regarding palliative versus curative intent of treatment, and those with missing 
county information (N = 4). We also excluded women who were identified as Hispanic or 
“Other” race (N = 125) given our focus on differences between African-American and white 
women, and due to the relatively small percentage (3 %) of women in these categories 
within the private insurance groups in the state. Finally, we excluded women whose estrogen 
receptor status was negative or unknown (N = 1,226) because they would be not be 
appropriate candidates for endocrine therapy (Fig. 1). There were 2,640 women who met all 
study inclusion and exclusion criteria.
Ascertainment of endocrine therapy initiation
Initiation of endocrine therapy was measured in two ways. First, we defined initiation as a 
dichotomous variable as having at least one drug claim for tamoxifen or an aromatase 
inhibitor (anastrozole, letrozole, or exemestane) within 12 months of diagnosis. Second, 
among those who started on endocrine therapy, we calculated the time in days from 
diagnosis to the first dispensing for endocrine therapy to identify time until therapy 
initiation.
Covariates
Using data reported to the North Carolina Central Cancer Registry, we identified the 
following control variables measured at the time of the patient’s diagnosis: patient age, race, 
year of diagnosis, cancer stage, tumor grade, and county of residence. For patients who had 
a full year of insurance enrollment prior to diagnosis, we used linked administrative 
insurance claims data to characterize medical comorbidity using the Klabunde modification 
of the Charlson index [19] and a separate algorithm for depression using the methods of 
Dusetzina et al. [20]. Women who did not have a full year of insurance enrollment prior to 
diagnosis (7 %) were assigned an “unknown” value for comorbidity score. We measured 
receipt of primary therapy, including breast-conserving surgery (BCS) or mastectomy, 
receipt of chemotherapy and receipt of radiation therapy during the 9 months post-diagnosis 
for surgery, and the 12 months post-diagnosis for radiation and chemotherapy.
Analytic strategy
First, we estimated the likelihood of receiving endocrine therapy during the 12 month period 
in the entire cohort. We used generalized estimating equations with a log link and Poisson 
distribution to generate the average risk of endocrine therapy initiation by race, adjusting for 
other measured covariates.
Reeder-Hayes et al. Page 4













Next, we estimated hazard ratios for endocrine therapy initiation by race using Cox 
Proportional Hazard Models. When testing proportional hazards assumptions for our 
primary analysis, we found that these assumptions were not met for the indicator addressing 
receipt of chemotherapy. Because of this, we stratified the Cox Proportional Hazards 
analyses by chemotherapy receipt when evaluating racial differences in initiation over time, 
adjusting for all other measured covariates. We used SAS 9.3 (Cary, NC) for analyses.
Sensitivity analyses
Because of concerns that African-American women may be more likely to have delays in 
treatment initiation than whites, pre-specified sensitivity analyses were performed to 
measure endocrine therapy initiation and time to initiation in an 18 month (versus 12 month) 
window.
Results
Of the 2,640 women included in our sample, 295 (11 %) were African-American and 2,345 
(89 %) were white. African-American women were more likely than white women to have 
poorly differentiated tumors, to have chemotherapy within the year following their 
diagnosis, and to be public employees within the state (Table 1). Overall, 79.7 % of African-
American women and 86.7 % of white women initiated endocrine therapy within 1 year of 
diagnosis. As compared to white women, African-American women were 17 % less likely to 
initiate endocrine therapy during the 12 months following their diagnosis (adjusted risk ratio 
[aRR]: 0.83, 95 % Confidence Interval [CI]: 0.74–0.93) (Table 2). Factors associated with a 
higher likelihood of endocrine therapy initiation in our multivariate model included having 
stage I (versus Stage III disease), and having well-or moderately differentiated tumors 
(versus poorly differentiated tumors). Conversely, receipt of chemotherapy within the year 
following diagnosis was associated with lower likelihood of initiating endocrine therapy 
(Table 2).
When estimating the time to endocrine therapy initiation stratified by chemotherapy receipt, 
we found that among women treated with chemotherapy (N = 1515), African-American 
women were significantly less likely than white women to initiate ET within 12 months of 
diagnosis (adjusted hazard ratio [aHR]: 0.67, 95 % Confidence Interval [CI]: 0.56–0.80). 
However, there was no difference in endocrine therapy initiation by race among women who 
did not receive chemotherapy (N = 1125)(aHR: 0.96, CI: 0.76–1.21) (Table 3, Fig. 2). Other 
factors associated with likelihood of ET initiation in chemotherapy-treated women, but not 
in non-chemotherapy-treated women, included stage, tumor grade, and receipt of 
mastectomy without radiation. However, the subset of non-chemotherapy-treated women 
who received breast conserving surgery without radiation as their primary local therapy was 
markedly less likely to initiate (aHR: 0.37, CI: 0.20–0.65).
Due to concerns that delays in primary therapies might push the initiation of endocrine 
therapy beyond 12 months post-diagnosis, we performed sensitivity analyses extending our 
follow-up time for identifying initiation of endocrine therapy from 12 to 18 months (data not 
shown). These results were similar to our primary analyses, specifically in that there did not 
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appear to be a “catch-up” phenomenon among African-American women in ET initiation 
between 12 and 18 months.
Discussion
In our analysis of commercially insured North Carolina women with early stage hormone-
receptor positive breast cancer, African-American race was associated with a significantly 
lower likelihood of endocrine therapy initiation. Further, the racial gap in endocrine therapy 
initiation appeared to be limited to women receiving more intensive overall treatment 
including chemotherapy. This finding adds to previous research documenting treatment 
disparities in other aspects of breast cancer care, and raises significant concerns regarding 
whether African-American women at high risk of cancer recurrence are receiving one 
potentially efficacious treatment only to miss out on another.
We found that among women whose treatment did not include chemotherapy, African-
American women were as likely as their white counterparts to initiate endocrine therapy. To 
our knowledge, our study is the first to note this relationship among race, chemotherapy 
receipt, and endocrine therapy utilization. Several potential explanations exist for this 
finding. Vulnerable women may have a better chance to initiate endocrine therapy if it is 
offered closer to the time of diagnosis before loss to follow-up can occur. Intervening 
chemotherapy complications may make certain women less likely to pursue further 
treatment or risk further side effects, particularly if their social support or financial resources 
have already been strained by earlier treatments. Alternatively, receipt of chemotherapy may 
reassure women that their risk has been eliminated, decreasing their perceived need for ET, 
and this perception may vary by race. Finally, the additional stresses to social support and 
financial resources brought on by chemotherapy may pose barriers to accessing ET, such as 
lack of transportation to appointments or pharmacies, or lack of ability to afford co-
payments, and these stresses may differentially impact minority women.
We found that women with stage III disease are less likely to initiate endocrine therapy 
independent of their race. We also noted that women with high grade tumors were less likely 
to initiate. While the association of higher risk disease with lower likelihood of ET initiation 
is counter-intuitive, it follows the pattern of prior work by Hershman et al. showing that 
women with lymph node-positive breast cancers were more likely to be non-adherent (taking 
<80 % of prescribed doses) to ET after initiation than women with earlier stage disease. [11] 
While our analysis did not examine specific chemotherapy regimens, it is possible that 
women with more biologically aggressive disease received more intensive chemotherapy 
regimens, adding to the barriers to initiation posed by chemotherapy-related complications, 
or that less attention was focused on education regarding endocrine therapy due to 
competing needs related to other treatments. Alternatively, it is possible that women who 
present with more advanced disease, perhaps as a result of screening non-adherence, poor 
access to health care or low health literacy, are also less likely to follow recommendations 
for ET.
This study had several limitations. We are unable to determine whether patients received 
prescriptions for ET that were never filled, or whether no ET was prescribed. While we did 
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control for availability of oncology services and income differences at the census tract level, 
we were unable to measure individual patient differences in socioeconomic status or access 
to care that may affect initiation behavior. In a claims-based analysis, we are also unable to 
examine factors such as social support, patient beliefs, and attitudes, or provider 
communication that may be key determinants of initiation behavior. Our findings come from 
a relatively young cohort of breast cancer survivors and may not apply to women over 65 
and uninsured or publicly insured women. However, the finding of a significant race 
disparity in this cohort of relatively healthy and well-insured women raises significant 
concerns regarding ET initiation in populations such as the elderly and women in poverty, 
where race effects may be compounded by other vulnerabilities. Further exploration of ET 
utilization in minority women from these doubly vulnerable populations is urgently needed. 
Evaluation of the relationship between race and ET uses after initiation, including 
persistence (continuing to take medication) and adherence (taking ET at the prescribed dose 
and schedule), was not within the scope of this analysis, but is planned in future work.
Future research will be most useful if it builds on these observational findings to explore 
attitudes, beliefs, and barriers that prevent women from utilizing appropriate, safe, and 
relatively inexpensive endocrine therapies to decrease their risk of breast cancer recurrence 
and death. A variety of research methods including the collection of qualitative and 
quantitative patient-reported data regarding ET medication taking behaviors, as well as the 
development of culturally sensitive interventions to increase ET utilization, hold promise for 
narrowing the survival gap among African-American women with hormone-receptor 
positive breast cancer.
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Cumulative rates of endocrine therapy initiation by race at 12 months post-diagnosis among 
chemotherapy-treated women (panel a) and women who did not receive chemotherapy 
(panel b)
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Table 2
Results of incidence proportion model for overall cohort
Variable RR 95 % CI
Race Black 0.83** (0.74–0.93)
White 1.00 –










Stage at diagnosis Stage I 1.16* (1.02–1.32)
Stage II 1.09 (0.97–1.21)
Stage III 1.00 –
Local therapy BCS, no radiation 0.48** (0.33–0.70)
BCS + radiation 1.00 –
Mastectomy, no radiation 1.05 (0.96–1.16)
Mastectomy + radiation 1.00 (0.90–1.10)
Tumor grade Well differentiated 1.19** (1.06–1.32)
Moderately differentiated 1.17** (1.08–1.27)
Poorly differentiated 1.00 –
Unkown/not assessed 0.99 (0.81–1.21)
Chemo within 1 year Yes 0.67** (0.61–0.74)
No 1.00 –
NCI combined comorbidity indexa 0 1.00 –
1+ 1.01 (0.89–1.14)
Unable to assess 0.97 (0.87–1.08)
Pre-existing depressiona Yes 0.99 (0.86–1.13)
No/unable to assess 1.00 –
Insurance plan type public employee 1.00 –
Other 0.94 (0.87–1.01)
# hospitals with oncology services in county of residence Lowest quartile 1.00 –
Low-mid quartile 0.89* (0.79–1.00)
High-mid quartile 1.01 (0.92–1.12)
Highest quartile 0.97 (0.88–1.08)
% poverty in county of residence Lowest quartile 1.00 –
Low-mid quartile 0.89* (0.80–0.99)
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Variable RR 95 % CI
High-mid quartile 0.91 (0.81–1.03)







Calculated using claims from 12 months prior to diagnosis. Patients enrolled for <12 months prior to diagnosis were designated ‘unable to assess’
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